Chemotherapy and Anlotinib Achieved 17 Months Progression-Free Survival in Rare Sarcoma Case
A case report documented a 17-month progression-free survival in a 23-year-old male with metastatic desmoplastic small round cell tumor treated ...
A case report documented a 17-month progression-free survival in a 23-year-old male with metastatic desmoplastic small round cell tumor treated ...
A real-world multicenter study in Türkiye reports that larotrectinib achieved high response rates in pediatric extracranial NTRK fusion-positive tumors, particularly ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.